Back
Apellis Pharmaceuticals 10K Form
Sell
34
APLS
Apellis Pharmaceuticals
Last Price:
$24.80
Seasonality Move:
7.92%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive APLS News And Ratings
See the #1 stock for the next 7 days that we like better than APLS
APLS Financial Statistics
Sales & Book Value
| Annual Sales: | $781.4M |
|---|---|
| Cash Flow: | $19.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.84 |
| Price / Book: | 13.63 |
Profitability
| EPS (TTM): | -1.59000 |
|---|---|
| Net Income (TTM): | $-197.9M |
| Gross Margin: | $663.6M |
| Return on Equity: | -83.06% |
| Return on Assets: | -22.95% |
Apellis Pharmaceuticals Earnings Forecast
Key Apellis Pharmaceuticals Financial Ratios
-
The Gross Profit Margin over the past 7 years for APLS is 84.93%.
-
The Selling, General & Administrative Expenses for APLS have been equal to 64.13% of Gross Profit Margin.
-
The Research & Development expenses have been 41.92% of Revenue.
-
The Net Earning history of APLS is -25.32% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 6 years.
Apellis Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | APLS |
| CUSIP: | 03753U |
| Website: | apellis.com |
Debt
| Debt-to-Equity Ratio: | 1.98 |
|---|---|
| Current Ratio: | 4.25 |
| Quick Ratio: | 3.68 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 1255.57 |
APLS Technical Analysis vs Fundamental Analysis
Sell
34
Apellis Pharmaceuticals (APLS)
is a Sell
Is Apellis Pharmaceuticals a Buy or a Sell?
-
Apellis Pharmaceuticals stock is rated a SellThe current Apellis Pharmaceuticals [APLS] share price is $24.81. The Score for APLS is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.